Therapeutic potential of midkine in cardiovascular disease

British Journal of Pharmacology

Volumn 171, Issue 4, 2014, Pages 936-944

  Kadomatsu, Kenji ^a   Bencsik, Péter ^b   Görbe, Anikõ ^b,c   Csonka, Csaba ^b,c   Sakamoto, Kazuma ^a   Kishida, Satoshi ^a   Ferdinandy, Péter ^b,d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b PHARMAHUNGARY GROUP   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

angiogenesis; apoptosis; brain; cardioprotection; heart; infarction; inflammation; ischaemia reperfusion; remodeling; vascular stenosis

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MIDKINE;

ANGIOGENESIS; ATHEROSCLEROSIS; CARCINOGENESIS; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; ENDOTHELIUM CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; NEOINTIMA; NEUROPROTECTION; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS; APOPTOSIS; BRAIN; CARDIOPROTECTION; HEART; INFARCTION; INFLAMMATION; ISCHAEMIA/REPERFUSION; REMODELING; VASCULAR STENOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION;

EID: 84893029600     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12537     Document Type: Review

References (72)

1. Asahara T, Kawamoto A, Masuda H, (2011). Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 29: 1650-1655.
2. Baluk P, Hashizume H, McDonald DM, (2005). Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102-111.
3. Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K, (2006). Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 44: 633-641.
4. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D, (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812.
5. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J, (2003). LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300: 329-332.
6. Broussalis E, Trinka E, Killer M, Harrer A, McCoy M, Kraus J, (2012). Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. Drug Discov Today 17: 671-684.
7. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
8. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al. (2013). Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153: 139-152.
9. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R, (1997). An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 1814-1819.
10. Claesson-Welsh L, (2012). Blood vessels as targets in tumor therapy. Ups J Med Sci 117: 178-186.
11. Cohen S, Shoshana OY, Zelman-Toister E, Maharshak N, Binsky-Ehrenreich I, Gordin M, et al. (2012). The cytokine midkine and its receptor RPTPzeta regulate B cell survival in a pathway induced by CD74. J Immunol 188: 259-269.
12. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34.
13. Dai LC, Wang X, Yao X, Lu YL, Ping JL, He JF, (2007). Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis. World J Gastroenterol 13: 1208-1213.
14. De Palma M, Lewis CE, (2013). Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23: 277-286.
15. Ferdinandy P, Schulz R, Baxter GF, (2007). Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59: 418-458.
16. Ferrara N, Henzel WJ, (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858.
17. Folkman J, (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
18. Fujita H, Banno H, Yamanouchi D, Kobayashi M, Yamamoto K, Komori K, (2008). Pitavastatin inhibits intimal hyperplasia in rabbit vein graft. J Surg Res 148: 238-243.
19. Fukui S, Kitagawa-Sakakida S, Kawamata S, Matsumiya G, Kawaguchi N, Matsuura N, et al. (2008). Therapeutic effect of midkine on cardiac remodeling in infarcted rat hearts. Ann Thorac Surg 85: 562-570.
20. Fukumura D, Jain RK, (2007). Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101: 937-949.
21. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.
22. Grothey A, Galanis E, (2009). Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518.
23. Harvey BK, Shen H, Chen GJ, Yoshida Y, Wang Y, (2004). Midkine and retinoic acid reduce cerebral infarction induced by middle cerebral artery ligation in rats. Neurosci Lett 369: 138-141.
24. Hausenloy DJ, Erik Botker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, et al. (2013). Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 98: 7-27.
25. Hayashi K, Banno H, Kadomatsu K, Takei Y, Komori K, Muramatsu T, (2005). Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury. Am J Physiol Heart Circ Physiol 288: H2203-H2209.
26. Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, Sakuma S, et al. (2000). Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 105: 489-495.
27. Horiba M, Kadomatsu K, Yasui K, Lee JK, Takenaka H, Sumida A, et al. (2006). Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction. Circulation 114: 1713-1720.
28. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
29. Ishiguro H, Horiba M, Takenaka H, Sumida A, Opthof T, Ishiguro YS, et al. (2011). A single intracoronary injection of midkine reduces ischemia/reperfusion injury in Swine hearts: a novel therapeutic approach for acute coronary syndrome. Front Physiol 2: 27.
30. Ishikawa E, Ooboshi H, Kumai Y, Takada J, Nakamura K, Ago T, et al. (2009). Midkine gene transfer protects against focal brain ischemia and augments neurogenesis. J Neurol Sci 285: 78-84.
31. Jaipersad AS, Lip GY, Silverman S, Shantsila E, (2013). The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol 63: 1-11.
32. Kadomatsu K, Kishida S, Tsubota S, (2013). The heparin-binding growth factor midkine: the biological activities and candidate receptors. J Biochem 153: 511-521.
33. Kieran MW, Kalluri R, Cho YJ, (2012). The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med 2: a006593.
34. Kishida S, Mu P, Miyakawa S, Fujiwara M, Abe T, Sakamoto K, et al. (2013). Midkine promotes neuroblastoma through Notch2 signaling. Cancer Res 73: 1318-1327.
35. Lee SH, Suh HN, Lee YJ, Seo BN, Ha JW, Han HJ, (2012). Midkine prevented hypoxic injury of mouse embryonic stem cells through activation of Akt and HIF-1α via low-density lipoprotein receptor-related protein-1. J Cell Physiol 227: 1731-1739.
36. Lusis AJ, (2000). Atherosclerosis. Nature 407: 233-241.
37. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T, Noda M, (1999). A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 274: 12474-12479.
38. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M, (2013). Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 229: 176-185.
39. Marcelo KL, Goldie LC, Hirschi KK, (2013). Regulation of endothelial cell differentiation and specification. Circ Res 112: 1272-1287.
40. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A, (2001). The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20: 97-105.
41. Moore KJ, Tabas I, (2011). Macrophages in the pathogenesis of atherosclerosis. Cell 145: 341-355.
42. Muramaki M, Miyake H, Hara I, Kamidono S, (2003). Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy. Clin Cancer Res 9: 5152-5160.
43. Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T, (2000). LDL receptor-related protein as a component of the midkine receptor. Biochem Biophys Res Commun 270: 936-941.
44. Muramatsu T, (2010). Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 86: 410-425.
45. Murdoch C, Muthana M, Coffelt SB, Lewis CE, (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631.
46. Narita H, Chen S, Komori K, Kadomatsu K, (2008). Midkine is expressed by infiltrating macrophages in in-stent restenosis in hypercholesterolemic rabbits. J Vasc Surg 47: 1322-1329.
47. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL, (1996). The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56: 2515-2518.
48. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
49. Ota T, Ota K, Jono H, Fujimori H, Ueda M, Shinriki S, et al. (2010). Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis. Oral Oncol 46: 657-661.
50. Park C, Kim TM, Malik AB, (2013). Transcriptional regulation of endothelial cell and vascular development. Circ Res 112: 1380-1400.
51. Poole TJ, Coffin JD, (1989). Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. J Exp Zool 251: 224-231.
52. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K, (2000). Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by midkine. J Biochem 127: 269-277.
53. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, et al. (2001). Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-Activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 276: 15868-15875.
54. Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA, (2004). Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem 279: 37124-37132.
55. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. (2010). Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468: 824-828.
56. Risau W, (1997). Mechanisms of angiogenesis. Nature 386: 671-674.
57. Ruan M, Ji T, Wu Z, Zhou J, Zhang C, (2007). Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 36: 159-164.
58. Sakamoto K, Bu G, Chen S, Takei Y, Hibi K, Kodera Y, et al. (2011). Premature ligand-receptor interaction during biosynthesis limits the production of growth factor midkine and its receptor LDL receptor-related protein 1. J Biol Chem 286: 8405-8413.
59. Salama RH, Muramatsu H, Zou P, Okayama M, Muramatsu T, (2006). Midkine, a heparin-binding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma cells. Cancer Lett 233: 16-20.
60. Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, et al. (2001). Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 167: 3463-3469.
61. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF, (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
62. Shachar I, Cohen S, Marom A, Becker-Herman S, (2012). Regulation of CLL survival by hypoxia-inducible factor and its target genes. FEBS Lett 586: 2906-2910.
63. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. (2002). Nuclear targeting by the growth factor midkine. Mol Cell Biol 22: 6788-6796.
64. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT, et al. (2002). Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277: 35990-35998.
65. Sumi Y, Muramatsu H, Takei Y, Hata K, Ueda M, Muramatsu T, (2002). Midkine, a heparin-binding growth factor, promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J Cell Sci 115 (Pt 13): 2659-2667.
66. Takada J, Ooboshi H, Ago T, Kitazono T, Yao H, Kadomatsu K, et al. (2005). Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia. Gene Ther 12: 487-493.
67. Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S, Muramatsu T, (1997). Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 122: 453-458.
68. Takenaka H, Horiba M, Ishiguro H, Sumida A, Hojo M, Usui A, et al. (2009). Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. Am J Physiol Heart Circ Physiol 296: H462-H469.
69. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. (2010). Regulation of the HIF-1α level is essential for hematopoietic stem cells. Cell Stem Cell 7: 391-402.
70. Tazzyman S, Lewis CE, Murdoch C, (2009). Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 90: 222-231.
71. Van Meter ME, Kim ES, (2010). Bevacizumab: current updates in treatment. Curr Opin Oncol 22: 586-591.
72. Weckbach LT, Groesser L, Borgolte J, Pagel JI, Pogoda F, Schymeinsky J, et al. (2012). Midkine acts as proangiogenic cytokine in hypoxia-induced angiogenesis. Am J Physiol Heart Circ Physiol 303: H429-H438.